BioInvent International AB (publ), a clinical-stage company, discovers, researches, and develops immuno-modulatory antibodies for the treatment of cancer in Sweden, Europe, the United States, Japan, and internationally. Its lead drug candidate is BI-1206 for the treatment of non-Hodgkin lymphoma and solid tumors. The company also develops tumor associated myeloid cells; cancer-associated regulatory T cells, which modulate the immune system; BT-001 in solid tumors; and BI-1808 and BI-1910, which are anti-TNFR2 antibodies for the treatment of solid tumors and cutaneous T-cell lymphoma. It has a strategic collaboration with Pfizer Inc. for the development of antibodies against tumor-associated myeloid cells; partnership and collaboration with Transgene to co-develskylinop multi-functional oncolytic viruses for treatment of solid tumors; and collaboration and supply agreement with Merck for the clinical development of BI-1808. The Company was incorporated in 1996 and is based in Lund, Sweden.

BioInvent International AB (publ)

BioInvent is a clinical-stage company that discovers and develops antibodies for cancer therapy, self-described as having one of the most unique cancer immunotherapy pipelines of any European biotech company.

msh id	COM:BIOINVENT
symbol	BINV
name	BioInvent International AB (publ)
homepage url	https://www.bioinvent.com
country	SE
sector	Healthcare
industry	Biotechnology
market	STOCKS
employee count	109
crunchbase url	-
linkedin url	-
founders	-

market cap	221.36M
enterprise value	-
stage	-
raised capital	-
valuation	-

monthly webtraffic	-
monthly webtraffic growth	-
growth score 14	-
growth score 28	-
growth score 90	-
growth score 365	-

revenue ltm	-
gross profit ltm	-
ebitda ltm	-
net income ltm	-
revenue ntm	-
gross profit ntm	-
ebitda ntm	-
net income ntm	-

growth cost and expenses	0.17
growth cost of revenue	-
growth depreciation and amortization	-0.3
growth ebitda	-12.04
growth ebitda ratio	-58.52
growth eps	-
growth eps diluted	-
growth general and administrative expenses	-1
growth gross profit	-0.78
growth gross profit ratio	-

BINV

COM:BIOINVENT

BioInvent

Last Close

45.65

21/11 16:29

Market Cap

2.36B

Beta: -

Volume Today

35.28K

Avg: -

Company Information

Market Metrics

Web & Growth Metrics

LTM & NTM Metrics

Growth & Performance Metrics

Operating Metrics

Balance Sheet Metrics

Financial Metrics (2022-2026)

cost and expenses	40.77M
cost of revenue	40.77M
depreciation and amortization	1.55M
ebitda	-32.63M
ebitda ratio	-4.95
eps	-0.46
eps diluted	-0.46
operating expenses	39.23M
operating income	-34.18M
operating income ratio	-5.19

accounts receivables	-
capital expenditure	-1.23M
cash at beginning of period	47.5M
cash at end of period	23.94M
inventory	1.09M
working capital ttm	1.17B

	2022	2023	2024	2025	2026
Revenue Metrics
Revenue	-	-	-	-	-
Revenue Growth	-	-	-	-	-
Revenue Multiple	-	-	-	-	-
Profit Metrics
Gross Profit	-	-	-	-	-
Gross Profit Growth	-	-	-	-	-
Gross Profit Multiple	-	-	-	-	-
EBITDA Metrics
EBITDA	-	-	-	-	-
EBITDA Growth	-	-	-	-	-
EBITDA Multiple	-	-	-	-	-
Net Income Metrics
Net Income	-	-	-	-	-
Net Income Growth	-	-	-	-	-
Net Income Multiple	-	-	-	-	-